JAC Advance Access published online on June 6, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl241
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Intensive Care, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium; Health Care Department, Hogeschool Gent ‘Vesalius’, 9000 Ghent, Belgium
* To whom correspondence should be addressed. Background: Fluconazole is an antifungal agent that is widely used for the treatment of Candida infection. Because of its favourable safety profile it is extensively used for prophylaxis in patient populations with a substantial risk for Candida infection. At the individual patient level, exposure to fluconazole selects for Candida non-albicans strains such as Candida glabrata and Candida krusei, with reduced susceptibility or intrinsic resistance to fluconazole. The effect of the volume of consumption of fluconazole on candidal ecology, however, is poorly investigated. Objectives: The long-term effect of fluconazole consumption on distribution of species causing candidaemia was investigated in a university hospital during an 11 year period (1994-2004). Methods: In a historical cohort the incidence of nosocomial candidaemia (expressed per 100 000 patient days) was linked with volume consumption of fluconazole [expressed as defined daily doses (DDDs) per 100 000 patient days] and evaluated over time. Results: During the study period 308 episodes of candidaemia occurred (63.3% caused by Candida albicans). The incidence of candidaemia varied from 6.0 to 13.8 per 100 000 patient days. The percentage candidaemia caused by Candida non-albicans spp. varied between 21% and 50%. No trends in the number of candidaemias or in the proportion of C. albicans versus Candida non-albicans spp. were observed. Fluconazole consumption was high but stable ranging from 5013 to 6807 DDDs per 100 000 patient days. No relationship could be demonstrated between volume of fluconazole consumption and Candida spp. distribution (Pearson's correlation coefficient: -0.083; P = 0.808). Conclusions: Despite long-term exposure to fluconazole, no change in candidal ecology was observed.
Received January 2, 2006
Revised May 15, 2006
Accepted May 16, 2006
Brief report
Effect of fluconazole consumption on long-term trends in candidal ecology
S. Blot 1 *,
R. Janssens 2,
G. Claeys 3,
E. Hoste 2,
F. Buyle 4,
J. J. De Waele 2,
R. Peleman 5,
D. Vogelaers 5,
and
K. Vandewoude 1
2 Department of Intensive Care, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
3 Department of Microbiology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
4 Hospital Pharmacy, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
5 Department of Infectious Diseases, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
S. Blot, E-mail: stijn.blot{at}UGent.be
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P Manzoni, M Mostert, E Jacqz-Aigrain, and D Farina The use of fluconazole in neonatal intensive care units Arch. Dis. Child., December 1, 2009; 94(12): 983 - 987. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tumbarello, M. Sanguinetti, E. M. Trecarichi, M. La Sorda, M. Rossi, E. de Carolis, K. de Gaetano Donati, G. Fadda, R. Cauda, and B. Posteraro Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome J. Antimicrob. Chemother., December 1, 2008; 62(6): 1379 - 1385. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Vandijck, S. I. Blot, L. Vandekerckhove, and D. P. Vogelaers Fluconazole Exposure and Selection for Candida Non-albicans Anesth. Analg., December 1, 2008; 107(6): 2091 - 2091. [Full Text] [PDF] |
||||
![]() |
G. Dimopoulos and M. E. Falagas Selection for Candida Non-albicans spp. After Fluconazole Use Anesth. Analg., December 1, 2008; 107(6): 2091 - 2092. [Full Text] [PDF] |
||||
![]() |
D. M Vandijck, S. I Blot, and J. M Decruyenaere Comment: Epidemiology, Risk Factors, and Outcomes of Candida albicans Versus Non-albicans Candidemia in Nonneutropenic Patients Ann. Pharmacother., November 1, 2007; 41(11): 1916 - 1917. [Full Text] [PDF] |
||||
![]() |
P. Manzoni, I. Stolfi, L. Pugni, L. Decembrino, C. Magnani, G. Vetrano, E. Tridapalli, G. Corona, C. Giovannozzi, D. Farina, et al. A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates N. Engl. J. Med., June 14, 2007; 356(24): 2483 - 2495. [Abstract] [Full Text] [PDF] |
||||




